Western Australian Therapeutics Advisory Group (WATAG)

The Western Australian Therapeutics Advisory Group (WATAG) promotes rational therapeutic drug use and provides independent advice to health professionals and health services on issues relating to the use of drugs and therapeutics in Western Australian public hospitals and the wider community.

WATAG has representation on the Council for Australia Therapeutic Advisory Groups (CATAG). The function of CATAG is to enable interjurisdictional communication, information sharing and collaboration to develop nationally consistent positions that promote the optimum use of medicines in hospitals.

The WATAG committees include:

Critical medicines list

Information presented on the WA Critical Medicines List is for general guidance only.

The stockholding values on the WA Critical Medicines List are provided as a general indication of quantity. Actual quantities held at an individual site will vary due to usage, stock expiration and supply issues. For more information about actual stock at any particular time, and access to stock in emergency situations, please contact the individual site.

The information on the WA Critical Medicines List is reviewed and endorsed by the WA Toxicology Service. The list is provided by the State of Western Australia as general guidance only and must not be relied on or used as a substitute for seeking advice from a qualified health practitioner. It is the user’s responsibility to verify the accuracy, currency, reliability and correctness of the information.

View the Critical medicines list (PDF 196KB)

Clinical guidelines and advisory notes

WATAG

WACA

WADEP

  • Cannabis based products quick guide (PDF 426KB)
  • Idarucizumab for reversal of anticoagulant effect of dabigatran – please refer to Formulary 1
  • Melatonin Formulary note – please refer to Formulary 1
  • Nivolumab Formulary note – please refer to Formulary 1
  • Palivizumab prophylaxis for respiratory syncitial virus in infants (PDF 1MB)
  • Rifaximin in hepatic encephalopathy guidelines – please refer to Formulary 1
  • Rituximab Inflammatory Myositis Advisory Note – please refer to Formulary 1
  • Rituximab NMDAR Encephalitis Advisory Note – please refer to Formulary 1
  • Rituximab Pemphigus Advisory Note – please refer to Formulary 1
  • Silodosin Formulary note – please refer to Formulary 1
  • Sugammadex guidelines – please refer to Formulary 1 
  • Tapentadol Formulary note – please refer to Formulary 1

WAMSG

Please see the Medication safety resource page for any clinician and/or consumer resources.

Items for external printer services for printing hard copies

WAPDC

Graylands Drug Bulletins

More information

WATAG
Office of the Chief Medical Officer
Address: 189 Royal Street
East Perth WA 6004
Phone: (08) 9222 6450
Email: WATAG@health.wa.gov.au